10q10k10q10k.net
ARTIVION, INC.

ARTIVION, INC.AORTEarnings & Financial Report

NYSE

Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.

NextMar 31, 2026

AORT Q3 2025 Key Financial Metrics

Revenue

$113.4M

Gross Profit

$74.4M

Operating Profit

$12.5M

Net Profit

$6.5M

Gross Margin

65.6%

Operating Margin

11.1%

Net Margin

5.7%

YoY Growth

18.4%

EPS

$0.13

Financial Flow

ARTIVION, INC. Q3 2025 Financial Summary

ARTIVION, INC. reported revenue of $113.4M for Q3 2025, with a net profit of $6.5M (5.7% margin). Cost of goods sold was $39.0M, operating expenses totaled $61.9M.

Key Financial Metrics

Total Revenue$113.4M
Net Profit$6.5M
Gross Margin65.6%
Operating Margin11.1%
Report PeriodQ3 2025

ARTIVION, INC. Annual Revenue by Year

ARTIVION, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $388.5M).

YearAnnual Revenue
2024$388.5M
2023$354.0M
2022$313.8M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$93.7M$97.4M$98.0M$95.8M$97.3M$99.0M$113.0M$113.4M
YoY Growth18.0%17.1%9.8%9.0%3.9%1.6%15.3%18.4%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$792.4M$784.0M$789.5M$803.1M$789.1M$791.2M$838.4M$857.7M
Liabilities$510.6M$489.0M$494.5M$498.4M$512.9M$496.9M$418.5M$419.0M
Equity$281.8M$295.0M$295.1M$304.7M$276.2M$294.3M$419.9M$438.7M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$10.8M$-5.5M$6.1M$11.5M$10.1M$-17.0M$15.0M$22.3M